Application of Immunoenhancing Radiotherapy in Treating Unresectable Intrahepatic Cholangiocarcinoma: A Case Report
Journal Title: Diseases & Research - Year 2024, Vol 4, Issue 1
Abstract
Unresectable intrahepatic cholangiocarcinoma currently lacks standard treatment methods. This report presents a case where PET/CT scans showed a subcapsular mass in the right posterior lobe of the liver measuring 6.2 cm × 3.7 cm × 3.8 cm, and a soft tissue nodule in the apicoposterior segment of the left upper lung lobe measuring 1.2 cm × 1.3 cm × 1.4 cm, both exhibiting increased glucose metabolism. A biopsy of the liver lesion confirmed well-differentiated cholangiocarcinoma, classified as Stage IV (cT1bN0M1). The patient, supported by their family, declined chemotherapy, surgery, immune checkpoint inhibitor therapy, and targeted therapy. Following a multidisciplinary team discussion, the patient was treated with conformal intensity-modulated radiotherapy aimed at the hepatic lesion, delivering a total dose of 50 Gy in ten sessions (5 Gy per session, once daily, five times per week). This was combined with 300 µg of granulocyte-macrophage colony-stimulating factor (GM-CSF), subcutaneously injected daily from the first to the tenth day of radiotherapy. No subsequent treatments were administered; only follow-up evaluations were performed. MRI assessments at three, twelve-, and twenty-four months post-treatment showed progressive reduction in the size of the hepatic primary lesion, with decreases of 15%, 36%, and 53% from baseline, respectively, and no growth in the pulmonary lesion. This outcome suggests that radiotherapy paired with an immunoadjuvant could be a viable treatment alternative for patients with unresectable intrahepatic cholangiocarcinoma.
Authors and Affiliations
Peng Jiang, Yingqi Zhang, Chenxing Shang, Jun Lu
Keywords
Related Articles
- EP ID EP740228
- DOI 10.54457/DR.202401006
- Views 42
- Downloads 1
Is Preoperative Radiotherapy Necessary for Resectable Locally Advanced Squamous Cell Esophageal Carcinoma?
Based on the guidelines for esophageal and esophagogastric junction cancers, the standard of care for resectable locally advanced (cT2, N0 [high-risk lesions: lymphovascular invasion, ≥3 cm, poorly differentiated]; cT1b-...
HBeAg Negativity is Associated with a Higher Risk of Liver-Related Death in Patients with Chronic Hepatitis B Related Liver Cirrhosis
Background and aims Few studies reported the association between the survival of patients with chronic hepatitis B (CHB)-related liver cirrhosis (LC) and hepatitis B e antigen (HBeAg) state. Methods Three hundred and ni...
Secretome of Dental Pulp-Derived Stem Cells Reduces Inflammation and Proliferation of Glioblastoma Cells by Deactivating Mapk-Akt Pathway
Background Dental pulp-derived stem cells (DPSC) is a promising therapy as they modulate the immune response, so we evaluated the inhibitory effect of DPSC secretome (DPSC℗) on the proliferation and inflammation in human...
Incidence of Side Effects During Tenofovir Alafenamide Monotherapy in Patients with Chronic Hepatitis B
Objective Tenofovir alafenamide (TAF) is a new prodrug of tenofovir that is widely used in chronic hepatitis B (CHB) patients, and its side effects have rarely been reported. We aimed to evaluate the incidence of side ef...
Multiparameter Flow Cytometry: An Important Auxiliary Tool for The Diagnosis and Differential Diagnosis of Myelodysplastic Neoplasms
Multiparameter flow cytometry (MFC) shows promise in the diagnosis and differential diagnosis of myelodysplastic neoplasms (MDS). By identifying abnormal immunophenotypes of different cell lineages in bone marrow (BM) ce...